Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 697,448 | 889,121 | 378,387 | 235,754 | 307,965 | 2,508,675 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 697,448 | 889,121 | 378,387 | 235,754 | 307,965 | 2,508,675 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 1,738,239 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 770,436 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 697,448 | 889,121 | 378,387 | 235,754 | 307,965 | 2,508,675 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 223 | 609 | 1,655 | 228 | 79 | 2,794 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 2,511,469 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| FOR REASONS SET FORTH BELOW, THE NATIONAL ROSACEA SOCIETY ("SOCIETY") BELIEVES THAT IT SHOULD BE TREATED AS A "PUBLICLY SUPPORTED ORGANIZATION PURSUANT TO THE "FACTS AND CIRCUMSTANCES" TEST DESCRIBED IN SECTION 1.170A-9(E)(3) OF THE INCOME TAX REGULATIONS.THE SOCIETY WAS INITIALLY ORGANIZED, AND HAS BEEN CONTINUOUSLY OPERATED, TO PROVIDE PHYSICIANS, PATIENTS AND THE GENERAL PUBLIC WITH EDUCATIONAL INFORMATION AND MATERIALS ON THE COMMON BUT LITTLE-KNOWN AND OFTEN LIFE-DISRUPTIVE SKIN DISORDER CALLED ROSACEA; TO SUPPORT EFFECTIVE PATIENT MANAGEMENT OF THIS CHRONIC AND OFTEN PROGRESSIVE DISEASE; AND TO SUPPORT RESEARCH RELATING TO POTENTIAL CAUSES AND OTHER KEY ASPECTS OF THE DISORDER. BETWEEN JANUARY 1, 2016 AND DECEMBER 31, 2020, THE SOCIETY HAS RECEIVED AN AGGREGATE AMOUNT OF $770,436 IN CASH DONATIONS AND CONTRIBUTIONS WHICH QUALIFY AS "PUBLIC SUPPORT." THIS AMOUNT CONSTITUTED 30.68% OF THE SOCIETY'S TOTAL SUPPORT FOR THE SAME PERIOD, WHICH EXCEEDS THE 10% MINIMUM LEVEL OF PUBLIC SUPPORT REQUIRED BY THE REGULATIONS.THE SOCIETY HAS MAINTAINED A CONTINUOUS AND BONA FIDE PROGRAM TO SOLICIT FUNDS FROM THE GENERAL PUBLIC. THIS SOLICITATION PROGRAM HAS BEEN IMPLEMENTED PRIMARILY THROUGH REQUESTS FOR CONTRIBUTIONS WHICH REGULARLY APPEAR IN THE SOCIETY'S NEWSLETTER THAT IS DISTRIBUTED WITHOUT CHARGE TO THE GENERAL PUBLIC. HOWEVER, THE SOCIETY'S NEWSLETTER IS READ PRIMARILY BY PEOPLE WHO SUFFER FROM ROSACEA AS WELL AS PHYSICIANS AND OTHER PERSONS WHO CARE FOR AFFLICTED INDIVIDUALS, AND THEREFORE, THE SOCIETY'S SOLICITATIONS HAVE REACHED A LIMITED AUDIENCE. THE SOCIETY BEGAN TO SIGNIFICANTLY BROADEN ITS FUND-RAISING ACTIVITIES TO INCLUDE HEALTH PROFESSIONALS, FOUNDATIONS AND INDUSTRY IN 2004, AND HAS CONTINUED TO EXPAND THESE ACTIVITIES IN ORDER TO REACH LARGER AUDIENCES.IN ADDITION, THE SOCIETY BELIEVES THE FOLLOWING FACTORS SUPPORT ITS CHARACTERIZATION AS A PUBLICLY SUPPORTED ORGANIZATION:1. THE SOCIETY HAS RECEIVED ITS PUBLIC SUPPORT FROM A LARGE, DIVERSE GROUP OF MORE THAN 85,000 INDIVIDUALS IN RELATIVELY SMALL CONTRIBUTION AMOUNTS, AS WELL AS A GROWING NUMBER OF MODERATE AMOUNTS FROM CORPORATIONS AND FOUNDATIONS.2. THE SOCIETY'S BOARD OF DIRECTORS IS COMPRISED OF VARIOUS UNRELATED INDIVIDUALS WHO HAVE AN INTEREST IN THE PROMOTION OF AWARENESS AND UNDERSTANDING OF THE DISEASE. NO MEMBER OF THE SOCIETY'S BOARD IS RELATED TO OR AFFILIATED WITH ANY SUBSTANTIAL DONOR TO THE SOCIETY.3. THE SOCIETY HAS FINANCIALLY SUPPORTED A NUMBER OF PUBLIC SERVICES AND RESEARCH ACTIVITIES WHICH PROVIDE A SUBSTANTIAL BENEFIT TO THE PUBLIC, ESPECIALLY THOSE PERSONS WHO ARE AFFLICTED WITH THE SKIN DISEASE ROSACEA OR WHO CARE FOR PERSONS WITH SUCH AFFLICTION. AMONG SUCH PROGRAMS FUNDED OR SPONSORED BY THE SOCIETY ARE THE FOLLOWING:A. INFORMATION SERVICES. THROUGH ITS TOLL-FREE TELEPHONE NUMBER, E-MAIL ADDRESS AND REGULAR MAIL, THE SOCIETY RECEIVES AND HANDLES MORE THAN 25,000 INQUIRIES A YEAR FROM INDIVIDUALS AND HEALTH PROFESSIONALS REQUESTING INFORMATION ON ROSACEA.B. WEB SITE. THE SOCIETY'S WEB SITE, ROSACEA.ORG, CONTAINS A WIDE VARIETY OF IN-DEPTH INFORMATION RELATING TO ROSACEA, AND WAS VIEWED BY 849,552 UNIQUE VISITORS IN 2020. THIS COMPREHENSIVE SITE RECEIVED A GOLD TRIANGLE AWARD FROM THE AMERICAN ACADEMY OF DERMATOLOGY FOR EXCELLENCE IN CONSUMER HEALTH INFORMATION.C. EDUCATIONAL MATERIALS. THE SOCIETY PRODUCES AND SUPPLIES EDUCATIONAL MATERIALS AT NO CHARGE IN RESPONSE TO REQUESTS FROM THE GENERAL PUBLIC AND HEALTH PROFESSIONALS EACH YEAR. THESE INCLUDE SUCH ITEMS AS EDUCATIONAL BOOKLETS ON UNDERSTANDING ROSACEA, MANAGING ROSACEA, LIFESTYLE MANAGEMENT, A PATIENT DIARY BOOKLET TO HELP SUFFERERS IDENTIFY AND AVOID TRIGGER FACTORS AFFECTING THEIR INDIVIDUAL CASES, A MEDICAL POSTER SHOWING THE CLASSIFICATION OF ROSACEA, MEDICAL OFFICE PLACARDS, THE ROSACEA REVIEW NEWSLETTER, MEDICAL JOURNAL ARTICLES AND BIBLIOGRAPHIES.D. NEWSLETTER. THE SOCIETY PUBLISHES A QUARTERLY NEWSLETTER ON ROSACEA, ROSACEA REVIEW, WHICH PROVIDES NEWS AND INFORMATION ON THE DISORDER FOR MORE THAN 387,000 PATIENTS AND HEALTH CARE PROFESSIONALS.E. AWARENESS PROGRAM. THROUGH ITS DESIGNATION OF APRIL AS ROSACEA AWARENESS MONTH EACH YEAR, AND PUBLIC SERVICE ANNOUNCEMENTS AND PUBLIC RELATIONS ACTIVITIES THROUGHOUT THE YEAR, THE SOCIETY REACHES AN ESTIMATED AUDIENCE OF MORE THAN 400 MILLION ANNUALLY, MANY OF WHOM MAY UNKNOWINGLY SUFFER FROM THIS CHRONIC AND POTENTIALLY LIFE-DISRUPTIVE DISORDER THAT AFFECTS AN ESTIMATED 16 MILLION AMERICANS.F. RESEARCH GRANTS PROGRAM. BECAUSE THE CAUSE OF ROSACEA IS UNKNOWN AND THERE IS NO CURE, THE SOCIETY ESTABLISHED A RESEARCH GRANTS PROGRAM BEGINNING IN 1999, WHICH FUNDS MEDICAL RESEARCH RELATING TO THE POTENTIAL CAUSES AND OTHER KEY ASPECTS OF THE DISORDER.4. THE SOCIETY ALSO SERVES AS A RESEARCH AND EDUCATIONAL ORGANIZATION, WHOSE WORKS ARE REGULARLY PUBLISHED IN MEDICAL JOURNALS AND ARE WIDELY USED BY MEDICAL RESEARCHERS, PHYSICIANS AND THE GENERAL PUBLIC. AMONG THE EDUCATIONAL AND RESEARCH ACTIVITIES FUNDED OR ORGANIZED BY THE SOCIETY ARE THE FOLLOWING:A. CONSENSUS CONFERENCES. BECAUSE OF ROSACEA'S WIDE RANGE OF POTENTIAL MANIFESTATIONS, THE SOCIETY HAS ORGANIZED AND SPONSORED CONSENSUS CONFERENCES OF LEADING AUTHORITIES ON ROSACEA AND EPIDEMIOLOGY TO DEVELOP WORLDWIDE STANDARDIZED CRITERIA FOR THE DISEASE, INCLUDING ITS DIAGNOSTIC, MAJOR AND SECONDARY FEATURES, WHICH WERE SIGNIFICANTLY UPDATED IN 2018; A STANDARDIZED GRADING SYSTEM FOR ASSESSING RELATIVE SEVERITY; AND A STANDARD MANAGEMENT OPTIONS SYSTEM THAT WAS SIGNIFICANTLY UPDATED IN 2020. THESE STANDARD CRITERIA ARE REVIEWED BY MEDICAL AUTHORITIES THROUGHOUT THE UNITED STATES AND WORLDWIDE, AND HAVE BEEN PUBLISHED IN MAJOR MEDICAL JOURNALS. THEY SERVE AS A STANDARD INSTRUMENT FOR UNIFYING THE FOCUS AND PARAMETERS OF ROSACEA RESEARCH WORLDWIDE, AND ARE ESSENTIAL TO ALLOW DATA FROM DIFFERENT SOURCES TO BE COMPARED AND EVALUATED. THE STANDARD CRITERIA ALSO AID IN CLINICAL DIAGNOSIS AND PATIENT CARE, AND PROVIDE STANDARD TERMINOLOGY FOR CLEAR COMMUNICATIONS ON ROSACEA AMONG RESEARCHERS, PHYSICIANS, HEALTH ADMINISTRATORS, PATIENTS AND THE GENERAL PUBLIC.B. PATIENT SURVEYS. BECAUSE OF THE SOCIETY'S UNIQUE ACCESS TO MANY THOUSANDS OF ROSACEA SUFFERERS THROUGH ITS NEWSLETTER AND WEB SITE, IT IS ABLE TO CONDUCT SURVEYS WITH LARGE PATIENT SAMPLES ON TRIGGER FACTORS, HEREDITY, AGE OF ONSET, SPEED OF PROGRESSION, IMPACT ON QUALITY OF LIFE AND OTHER SIGNIFICANT ASPECTS OF ROSACEA. THE SURVEY RESULTS ARE PUBLISHED IN MEDICAL JOURNALS, ARE OFTEN CITED IN OTHER MEDICAL ARTICLES AND PRESENTATIONS, AND ARE USED BY RESEARCHERS, PHYSICIANS AND PATIENTS.C. MEDICAL RESEARCH. SINCE THE CAUSE OF ROSACEA IS UNKNOWN, THE SOCIETY'S MEDICAL ADVISORY BOARD AWARDS RESEARCH GRANTS EACH YEAR FOR STUDIES RELATING TO POTENTIAL CAUSES AND OTHER KEY ASPECTS OF ROSACEA. SINCE THE ISSUING OF GRANTS BEGAN IN LATE 1999, $1,636,713 HAS BEEN AWARDED TO FUND 73 RESEARCH STUDIES, AND THE SOCIETY ANTICIPATES ISSUING GREATER NUMBERS OF GRANTS IN THE FUTURE. STUDY RESULTS ARE PRESENTED AT SCIENTIFIC AND MEDICAL MEETINGS, AND ARE PUBLISHED IN SCIENTIFIC AND MEDICAL JOURNALS.D. RESEARCH WORKSHOP. TO SHARE SCIENTIFIC KNOWLEDGE AND ENCOURAGE ROSACEA RESEARCH, THE SOCIETY HAS ORGANIZED AND CONDUCTED RESEARCH WORKSHOPS AT THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING. THE WORKSHOPS HAVE FEATURED PRESENTATIONS AND OPEN DISCUSSION AMONG ROSACEA EXPERTS AND ATTENDING MEDICAL RESEARCHERS ON NEW SCIENTIFIC INFORMATION AND VARIOUS ASPECTS OF THE DISEASE THAT SHOULD BE INVESTIGATED.E. TECHNICAL EXHIBITS. THE SOCIETY HAS PROVIDED TECHNICAL EXHIBITS FOR PHYSICIANS AT MAJOR MEDICAL MEETINGS, INCLUDING A WIDE RANGE OF MEDICAL EDUCATION INFORMATION ON THE DISEASE, AS WELL AS EDUCATIONAL MATERIALS FOR THEIR PATIENTS. |
| Return Reference | Explanation |
|---|---|
| 5. THE ACTIVITIES AND PROGRAMS OF THE SOCIETY HAVE ATTRACTED | PARTICIPATION OF A WIDE AND GROWING NUMBER OF PHYSICIANS, MEDICAL RESEARCHERS AND SCHOLARS WITH SPECIAL KNOWLEDGE OR INTEREST IN ROSACEA. THE SOCIETY'S NEWSLETTER IS EDITED BY DR. LYNN DRAKE OF HARVARD MEDICAL SCHOOL, WHO IS A FORMER PRESIDENT OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD). THE SOCIETY'S MEDICAL ADVISORY BOARD IS CHAIRED BY DR. RICHARD GRANSTEIN, CHAIRMAN OF DERMATOLOGY AT WEILL CORNELL MEDICAL COLLEGE. MEDICAL ADVISORY BOARD MEMBERS ALSO INCLUDE DR. DRAKE; DR. RICHARD GALLO, CHIEF OF DERMATOLOGY, UNIVERSITY OF CALIFORNIA-SAN DIEGO; DR. JULIE HARPER, CLINICAL ASSOCIATE PROFESSOR OF DERMATOLOGY, UNIVERSITY OF ALABAMA-BIRMINGHAM; DR. YOLANDA HELFRICH, ASSOCIATE PROFESSOR OF DERMATOLOGY, UNIVERSITY OF MICHIGAN; DR. MARK MANNIS, CHAIRMAN OF OPHTHALMOLOGY, UNIVERSITY OF CALIFORNIA-DAVIS; DR. MARTIN STEINHOFF, CHAIRMAN OF DERMATOLOGY, UNIVERSITY COLLEGE OF DUBLIN; DR. SEWON KANG, CHAIRMAN OF DERMATOLOGY, JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE; AND DR. HILARY BALDWIN, ASSOCIATE PROFESSOR OF DERMATOLOGY, RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL. THE CLASSIFICATION, GRADING AND MANAGEMENT OPTIONS CONSENSUS CONFERENCES ALSO INCLUDED DR. ALVAN FEINSTEIN, PROFESSOR OF MEDICINE AND EPIDEMIOLOGY AT YALE UNIVERSITY SCHOOL OF MEDICINE; DR. MATTHEW LIANG, PROFESSOR OF MEDICINE, DEPARTMENT OF HEALTH POLICY AND MANAGEMENT, HARVARD SCHOOL OF PUBLIC HEALTH; DR. ZOE DRAELOS, CONSULTING PROFESSOR OF DERMATOLOGY, DUKE UNIVERSITY; DR. JEFFREY DOVER, ASSOCIATE CLINICAL PROFESSOR OF DERMATOLOGY, YALE UNIVERSITY SCHOOL OF MEDICINE; DR. JERRY TAN, ADJUNCT PROFESSOR OF DERMATOLOGY, UNIVERSITY OF WESTERN ONTARIO; DR. DIANE THIBOUTOT, PROFESSOR OF DERMATOLOGY, PENNSYLVANIA STATE UNIVERSITY; AND DR. GUY WEBSTER, PROFESSOR OF DERMATOLOGY, THOMAS JEFFERSON UNIVERSITY. RESEARCH GRANTS HAVE BEEN AWARDED TO DR. MINA YAAR, PROFESSOR OF DERMATOLOGY AT BOSTON UNIVERSITY MEDICAL SCHOOL; DR. ETHAN A. LERNER, ASSOCIATE PROFESSOR OF DERMATOLOGY AT HARVARD MEDICAL SCHOOL; DR. PATRICIA FITZPATRICK, EPIDEMIOLOGIST WITH THE DEPARTMENT OF PUBLIC HEALTH MEDICINE & EPIDEMIOLOGY AT UNIVERSITY COLLEGE, DUBLIN; DR. FRANK POWELL, CONSULTANT DERMATOLOGIST, MATER MISERICORDIAE HOSPITAL, DUBLIN; DR. KEVIN KAVANAGH, DEPARTMENT OF BIOLOGY AT NATIONAL UNIVERSITY OF IRELAND; DR. PATRICK SCHLIEVERT, PROFESSOR OF MICROBIOLOGY AT UNIVERSITY OF MINNESOTA MEDICAL SCHOOL; DR. ROBERT A. SWERLICK, ASSOCIATE PROFESSOR OF DERMATOLOGY AT EMORY UNIVERSITY SCHOOL OF MEDICINE; DR. MARK DAHL, CHAIRMAN OF DERMATOLOGY, MAYO CLINIC-SCOTTSDALE; DR. RICHARD GALLO, CHIEF OF DERMATOLOGY, UNIVERSITY OF CALIFORNIA-SAN DIEGO; DRS. TAKAAKI OTAKE, MASAMOTO MURAKAMI, AND KENSHI YAMASAKI, VETERANS MEDICAL RESEARCH FOUNDATION, SAN DIEGO; DR. DIANE THIBOUTOT, PROFESSOR OF DERMATOLOGY, HILMA BENJAMIN, AND DR. KLAUS HELM, DIVISION OF DERMATOLOGY, PENNSYLVANIA STATE UNIVERSITY; DR. SANDRA JONES WU, ASSISTANT PROFESSOR OF DERMATOLOGY, DR. NICHOLAS FLAVAHAN, PROFESSOR OF MEDICINE, AND DR. NICONOR MOLDOVAN, ASSISTANT PROFESSOR OF MEDICINE, THE OHIO STATE UNIVERSITY; KAROL LINDOW, ASSOCIATE PROFESSOR OF NURSING, DEB SHELESTAK, AND MARY DALPIAZ, ASSISTANT PROFESSOR OF NURSING, KENT STATE UNIVERSITY; DR. RICHARD GRANSTEIN, CHAIRMAN OF DERMATOLOGY, AND DR. CYNTHIA MAGRO, DIRECTOR OF DERMATOPATHOLOGY, CORNELL UNIVERSITY; DR. WENDY ROBERTS, MEDICAL DIRECTOR, DESERT DERMATOLOGY MEDICAL ASSOCIATES, RANCHO MIRAGE, CALIFORNIA; DRS. RICHARD BURROUGHS, MARK PEAKE AND RICHARD VINSON, WILLIAM BEAUMONT ARMY MEDICAL CENTER; DR. SCOTT NORTON, CHIEF OF DERMATOLOGY, WALTER REED ARMY MEDICAL CENTER; DR. JOHN WERREN, PROFESSOR OF BIOLOGY, AND SETH BORDENSTEIN, UNIVERSITY OF ROCHESTER; DR. YOUWEN ZHOU, DIRECTOR OF THE CHIENG GENOMICS CENTER, UNIVERSITY OF BRITISH COLUMBIA, CANADA; DRS. MARTIN STEINHOFF AND THOMAS LUGER, DEPARTMENT OF DERMATOLOGY, UNIVERSITY OF MUENSTER, GERMANY; DR. ALBERT KLIGMAN, PROFESSOR OF DERMATOLOGY, AND DR. YAXIAN ZHEN, RESEARCHER, UNIVERSITY OF PENNSYLVANIA; DR. MARK MANNIS, CHAIRMAN OF OPHTHALMOLOGY, UNIVERSITY OF CALIFORNIA-DAVIS; DR. LENIO ALVARENGA, DEPARTMENT OF OPHTHALMOLOGY, FEDERAL UNIVERSITY OF SAO PAULO, BRAZIL; DR. PAYAM TRISTANI-FIROUZI, ASSISTANT PROFESSOR, AND DR. NANCY SAMOLITIS, VISITING PROFESSOR, DEPARTMENT OF DERMATOLOGY, UNIVERSITY OF UTAH; DR. SANDRA CREMERS, ASSISTANT PROFESSOR OF OPHTHALMOLOGY, HARVARD MEDICAL SCHOOL; DR. KENT KEYSER, PROFESSOR OF VISION SCIENCES, UNIVERSITY OF ALABAMA AT BIRMINGHAM; DR. YOLANDA HELFRICH, ASSISTANT PROFESSOR OF DERMATOLOGY, UNIVERSITY OF MICHIGAN; DR. ROBERT WALTERS, ASSISTANT PROFESSOR OF DERMATOLOGY AND DR. ROBERT LEFKOWITZ, PROFESSOR OF MEDICINE, DUKE UNIVERSITY; DR. CURDIN CONRAD, SENIOR POSTDOCTORAL RESEARCH FELLOW, MD ANDERSON CANCER CENTER; DR. ALEXANDER NAVARINI, SENIOR POSTDOCTORAL RESEARCH FELLOW, DEPARTMENT OF DERMATOLOGY, UNIVERSITY HOSPITAL OF ZURICH, SWITZERLAND; DRS. JOSEPH ROTHNAGEL AND MANUELA TRABI, DEPARTMENT OF MICROBIAL SCIENCES, UNIVERSITY OF QUEENSLAND, AUSTRALIA; DR. JAMISON FERAMISCO, MOLECULAR MEDICINE FELLOW IN DERMATOLOGY AT THE UNIVERSITY OF CALIFORNIASAN FRANCISCO; DR. THAD WILSON, ASSOCIATE PROFESSOR OF PHYSIOLOGY AND MEDICINE AT OHIO UNIVERSITY; DR. NOREEN LACEY, POSTDOCTORAL RESEARCHER AT UNIVERSITY COLLEGE DUBLIN; DR. FERDA CEVIKBAS, POSTDOCTORAL FELLOW, UNIVERSITY OF CALIFORNIA-SAN FRANCISCO; DR. EDWARD WLADIS, ASSISTANT PROFESSOR OF OPHTHALMOLOGY, ALBANY MEDICAL COLLEGE; DR. ANNA DI NARDO, ASSOCIATE PROFESSOR OF MEDICINE AT THE UNIVERSITY OF CALIFORNIA-SAN DIEGO; DRS. MEG GERSTENBLITH AND DANIEL POPKIN, ASSISTANT PROFESSORS OF DERMATOLOGY AT CASE WESTERN RESERVE UNIVERSITY; DRS. ULF MEYER-HOFFERT AND THOMAS SCHWARTZ OF THE DEPARTMENT OF DERMATOLOGY, UNIVERSITY CLINIC SCHLESWIG-HOLSTEIN; DR. BARBARA SUMMERER, POSTDOCTORAL RESEARCH FELLOW IN DERMATOLOGY AT JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE; AND DR. YOSHIKAZU UCHIDA, ASSOCIATE RESEARCH DERMATOLOGIST; DR. PETER ELIAS, PROFESSOR OF DERMATOLOGY, THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO; DR. ANNE CHANG, ASSISTANT PROFESSOR OF DERMATOLOGY, STANFORD UNIVERSITY SCHOOL OF MEDICINE; DR. LORI STOHL, RESEARCH ASSOCIATE IN DERMATOLOGY, CORNELL UNIVERSITY; DR. GIDEON SMITH, INSTRUCTOR OF DERMATOLOGY, HARVARD MEDICAL SCHOOL; DR. WENQING LI, ASSISTANT PROFESSOR OF DERMATOLOGY AT BROWN UNIVERSITY; DR. LUIS GARZA, ASSOCIATE PROFESSOR OF DERMATOLOGY AT JOHNS HOPKINS UNIVERSITY; DR. BENJAMIN KAFFENBERGER, ASSISTANT PROFESSOR OF DERMATOLOGY AT THE OHIO STATE UNIVERSITY; DR. RAJA SIVAMANI, ASSOCIATE PROFESSOR OF CLINICAL DERMATOLOGY AT THE UNIVERSITY OF CALIFORNIA-DAVIS; DR. HESTER LIM, POSTDOCTORAL RESEARCH FELLOW IN DERMATOLOGY AT JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE; DR. MICHELLE TRAUTWEIN, RESEARCHER AT THE INSTITUTE FOR BIODIVERSTY SCIENCE, CALIFORNIA ACADEMY OF SCIENCE; AND DR. TISSA HATA, CLINICAL PROFESSOR OF DERMATOLOGY, UNIVERSITY OF CALIFORNIA-SAN DIEGO. |
| OTHERS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO SOCIETY | PROGRAMS AND ACTIVITIES INCLUDE DR. JONATHAN WILKIN, FORMER DIRECTOR OF THE DERMATOLOGIC DIVISION, U.S. FOOD & DRUG ADMINISTRATION; DR. RICHARD ODOM, PROFESSOR OF CLINICAL DERMATOLOGY, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, AND A FORMER PRESIDENT OF AAD; DR. DAVID NORRIS, CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF COLORADO, AND A FORMER PRESIDENT OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY; DR. FRANK POWELL, CONSULTANT DERMATOLOGIST, REGIONAL CENTRE OF DERMATOLOGY, MATER MISERICORDIAE HOSPITAL, AND DIRECTOR, CHARLES INSTITUTE OF DERMATOLOGY AT UNIVERSITY COLLEGE DUBLIN, IRELAND, AND FORMER PRESIDENT, EUROPEAN ACADEMY OF DERMATOLOGY AND VENEROLOGY; DR. MICHAEL DETMAR, ASSOCIATE PROFESSOR OF DERMATOLOGY AT HARVARD MEDICAL SCHOOL AND PROFESSOR PHARMACOGENOMICS, FEDERAL INSTITUTE OF TECHNOLOGY, ZURICH, SWITZERLAND; DR. MARIAN MACSAI, VICE CHAIR OF OPHTHALMOLOGY, NORTHWESTERN UNIVERSITY; DR. ALEXA BOER KIMBALL, DIRECTOR OF CLINICAL RESEARCH TRIALS IN SKIN, HARVARD MEDICAL SCHOOL; DR. LARRY MILLIKAN, CHAIRMAN OF DERMATOLOGY AT TULANE MEDICAL SCHOOL; DR. JOHN WOLF, CHAIRMAN OF DERMATOLOGY AT BAYLOR UNIVERSITY; DR. JEROME LITT, ASSISTANT CLINICAL PROFESSOR OF DERMATOLOGY AT CASE WESTERN RESERVE UNIVERSITY; DR. JOSEPH BIKOWSKI, CLINICAL ASSISTANT PROFESSOR OF DERMATOLOGY AT THE OHIO STATE UNIVERSITY; DR. THOMAS CASH, PROFESSOR OF PSYCHOLOGY AT OLD DOMINION UNIVERSITY; DR. TED GROSSBART, CLINICAL PSYCHOLOGIST AT HARVARD MEDICAL SCHOOL; DR. PHILIP BAILIN, CHAIRMAN OF DERMATOLOGY AT THE CLEVELAND CLINIC FOUNDATION; DR. RONALD MOY, ASSOCIATE CLINICAL PROFESSOR OF DERMATOLOGY AT THE UNIVERSITY OF CALIFORNIA-LOS ANGELES AND FORMER PRESIDENT OF THE AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY; DR. JAMES DEL ROSSO, ASSISTANT CLINICAL PROFESSOR OF DERMATOLOGY, UNIVERSITY OF NEVADA SCHOOL OF MEDICINE; DR. JOEL BAMFORD, ASSOCIATE PROFESSOR OF FAMILY PRACTICE, UNIVERSITY OF MINNESOTA-DULUTH; DR. MATS BERG, DEPARTMENT OF DERMATOLOGY, UPPSALA UNIVERSITY IN SWEDEN; DR. RONALD MARKS, EMERITUS PROFESSOR OF DERMATOLOGY, UNIVERSITY OF WALES COLLEGE OF MEDICINE; DR. GERD PLEWIG, PROFESSOR OF DERMATOLOGY, LUDWIG-MAXIMILIANS UNIVERSITY IN GERMANY; DR. ALFREDO REBORA, PROFESSOR OF ENDOCRINOLOGY AND METABOLISM, UNIVERSITY OF GENOA IN ITALY; DR. JAMES T. ELDER, PROGRAMS PROFESSOR OF DERMATOLOGY, UNIVERSITY OF MICHIGAN; DR. MICHELLE PELLE, CLINICAL ASSISTANT PROFESSOR OF DERMATOLOGY, UNIVERSITY OF CALIFORNIA-SAN DIEGO; DR. LISA MAIER, ASSISTANT PROFESSOR OF DERMATOLOGY, UNIVERSITY OF MICHIGAN; DR. ROY GERONEMUS, CLINICAL PROFESSOR OF DERMATOLOGY, NEW YORK UNIVERSITY; DR. WILMA BERGFELD, SECTION HEAD, DERMATOPATHOLOGY AT THE CLEVELAND CLINIC FOUNDATION; DR. THEODORE ROSEN, PROFESSOR OF DERMATOLOGY, BAYLOR UNIVERSITY; DR. LINDA STEIN GOLD, DIRECTOR OF DERMATOLOGY CLINICAL RESEARCH, HENRY FORD HOSPITAL; DR. LUIZ ALMEIDA, DEPARTMENT OF DERMATOLOGY, FEDERAL UNIVERSITY OF MINAS GERAIS, BRAZIL; DR. ANTHONY BEWLEY, WHIPPS CROSS UNIVERSITY HOSPITAL AND ROYAL LONDON HOSPITAL; DR. NCOZA DLOVA, DEPARTMENT OF DERMATOLOGY, UNIVERSITY OF KWAZULU-NATAL COLLEGE OF HEALTH SCIENCES, SOUTH AFRICA; DR. JAMES DEL ROSSO, ADJUNCT CLINICAL PROFESSOR OF DERMATOLOGY, TOURO UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE.; DR. ALEXANDER EGEBERG, DEPARTMENT OF DERMATOALLERGOLOGY, HERLEV AND GENTOFTE UNIVERSITY HOSPITAL, UNIVERSITY OF COPENHAGEN, DENMARK; DR. FABIENNE FORTON, DERMATOLOGY UNIT, UNIVERSITE LIBRE DE BRUXELLES, BELGIUM; DR. MARTIN SCHALLER, PROFESSOR OF DERMATOLOGY, UNIVERSITTSKLINIKUM, TUBINGEN, GERMANY; AND DR. ESTHER VAN ZUUREN, DEPARTMENT OF DERMATOLOGY, LEIDEN UNIVERSITY MEDICAL CENTRE, THE NETHERLANDS; AND DR. RICHARD ANDERSON, PROFESSOR OF DERMATOLOGY, HARVARD MEDICAL SCHOOL. THE SOCIETY INTENDS TO CONTINUE TO ATTRACT AND EXPAND SUCH PARTICIPATION IN THE FUTURE. |
| 6. THE SOCIETY'S FAILURE TO MEET THE 33 1/3 PERCENT OF | SUPPORT TEST IN THE PAST WAS PRIMARILY DUE TO THE LARGE PERCENTAGE OF SUPPORT IT HAS HISTORICALLY RECEIVED FROM GALDERMA LABORATORIES, INC. HOWEVER, THE LEVEL OF SUPPORT FROM GALDERMA HAS SUBSTANTIALLY DECLINED AND THE SOCIETY HAS BEEN INFORMED BY GALDERMA THAT ITS SUPPORT WILL CONTINUE AT A LOWER LEVEL IN THE FUTURE. ACCORDINGLY, THE SOCIETY EXPECTS THAT, IN THE FORESEEABLE FUTURE, ITS FUNDING SOURCES WILL CONTINUE TO SUBSTANTIALLY DIVERSIFY AND CONTRIBUTIONS FROM THE PUBLIC WILL CONSTITUTE ITS PRIMARY SOURCE OF SUPPORT. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 | TO IMPROVE THE LIVES OF THOSE WHO SUFFER FROM ROSACEA BY RAISING AWARENESS, PROVIDING INFORMATION, AND SUPPORTING MEDICAL RESEARCH ON THIS WIDESPREAD BUT POORLY UNDERSTOOD SKIN DISORDER AFFECTING AN ESTIMATED 16 MILLION AMERICANS. |
| FORM 990, PART VI, SECTION A, LINE 2 | TWO OF THE SEVEN DIRECTORS OF THE NATIONAL ROSACEA SOCIETY (NRS), ANDREW F. HUFF AND MARY F. ERHARD, ARE EMPLOYED BY GLENDALE COMMUNICATIONS GROUP (GLENDALE). GLENDALE PROVIDES THE PERSONNEL AND INFRASTRUCTURE, AND CARRIES CERTAIN OUTSIDE EXPENSES, NEEDED TO SUPPORT AND IMPLEMENT THE PROGRAM SERVICES AND ADMINISTRATION OF THE NRS. GLENDALE ALSO PROVIDES SERVICES TO OTHER CLIENTS UNRELATED TO THE NRS. THE POSITIONS OF THESE NRS DIRECTORS WITH GLENDALE AND THEIR TOTAL SALARIES IN 2020 ARE AS FOLLOWS (ALSO REPORTED IN COLUMN E IN PART VII, SECTION A): ANDREW F. HUFF, EXECUTIVE VICE PRESIDENT, GLENDALE $61,616 MARY F. ERHARD, MEDICAL EDITOR, GLENDALE $9,901 SAMUEL B. HUFF, PRESIDENT, GLENDALE $50,562 BECAUSE OF THEIR RELATIONSHIP, NRS DIRECTORS ASSOCIATED WITH GLENDALE ABSTAIN FROM ALL BOARD OF DIRECTOR VOTES AFFECTING GLENDALE, AND ONLY THE NRS DIRECTORS NOT ASSOCIATED WITH GLENDALE (THE "INDEPENDENT NRS DIRECTORS") REVIEW AND APPROVE ACTIVITIES AND BUDGETS AFFECTING GLENDALE. EACH YEAR, THE INDEPENDENT NRS DIRECTORS REVIEW THE CONTINUATION OF THE NRS'S RELATIONSHIP WITH GLENDALE, AND MUST APPROVE RETENTION OF GLENDALE BY THE NRS ANNUALLY. IN ADDITION, AT LEAST ONE OF THE INDEPENDENT NRS DIRECTORS REVIEWS MONTHLY INVOICES FROM GLENDALE TO THE NRS. GLENDALE'S FEES TO THE NRS ARE DETERMINED ON THE SAME BASIS AS FOR OTHER GLENDALE CLIENTS, AND THE INDEPENDENT NRS DIRECTORS ARE PROVIDED WITH COMPETITIVE COST ESTIMATES FOR SPECIFIC PROJECTS UNDERTAKEN BY GLENDALE ON BEHALF OF THE NRS. |
| FORM 990, PART VI, SECTION A, LINE 2 | SAMUEL B. HUFF AND ANDREW F. HUFF HAVE A FAMILIAL RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | A COPY OF THE FORM 990 IS REVIEWED BY THE BOARD OF DIRECTORS BEFORE IT IS FILED. |
| FORM 990, PART VI, SECTION B, LINE 12C | COMPLIANCE WITH THE CONFLICT OF INTEREST POLICY IS REVIEWED AT BOARD MEETINGS. |
| FORM 990, PART VI, SECTION C, LINE 19 | AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 9: | RECOVERIES OF PRIOR YEAR GRANTS 11,657. |
| Software ID: | |
| Software Version: |